Allergan (NYSE:AGN) Releases Earnings Results, Meets Expectations

Allergan (NYSE:AGN) issued its quarterly earnings data on Tuesday. The company reported $4.25 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $4.25, Briefing.com reports. The firm had revenue of $4.03 billion during the quarter, compared to the consensus estimate of $3.88 billion. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the company earned $4.25 EPS. Allergan updated its FY19 guidance to >$16.55 EPS.

Shares of Allergan stock opened at $178.55 on Thursday. The business has a 50-day moving average of $171.07 and a 200 day moving average of $155.31. Allergan has a 12 month low of $114.27 and a 12 month high of $179.88. The stock has a market capitalization of $58.66 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 2.12 and a beta of 1.66. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.03 and a quick ratio of 0.91.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Wednesday, November 13th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.66%. The ex-dividend date of this dividend is Tuesday, November 12th. Allergan’s dividend payout ratio (DPR) is 17.74%.

A number of analysts recently issued reports on the company. Barclays raised their price objective on Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 7th. Royal Bank of Canada reissued a “hold” rating and set a $178.00 price objective on shares of Allergan in a research report on Thursday, August 8th. TheStreet raised Allergan from a “d+” rating to a “c” rating in a research report on Friday, July 12th. Cantor Fitzgerald raised their price objective on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Finally, Svb Leerink reissued a “market perform” rating and set a $188.00 price objective (down from $217.00) on shares of Allergan in a research report on Thursday, July 18th. Two investment analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $175.16.

Allergan Company Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

See Also: How Short Selling Works

Earnings History for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.